02137 BRII-B
- 1.020
- +0.040+4.08%
BRII-B News
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Tengshengbo Medicine -B (02137.HK) plans to hold a board of directors meeting on August 19 to approve its interim performance.
Tengshengbo Medicine-B (02137.HK) announced that the board of directors will hold a meeting on August 19, 2024 (Monday) to review and approve the unaudited interim performance of the company and its subsidiaries for the six months ended on June 30, 2024 and its publication, as well as to deal with other matters.
Brii Biosciences Says Unaffected by VBI Vaccines' Restructuring Under Creditors Arrangement Act, Shares Up 3%
Robert Taylor Nelsen resigned as non-executive director of Tengshengbo Medicine B (02137).
Tengshengbo Medicine-B (02137) released an announcement, Mr. Robert Taylor Nelsen...
Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference
Express News | Brii Bio Presents New Data From Its Ongoing Phase 2 Chronic Hepatitis B Trials at Easl™ Congress 2024
Tengshengbo Medicine-B (02137.HK) released new data from two phase 2 studies at the European Liver Research Association Congress in 2024.
On June 7th, National Business Daily announced that Tengshengbo Medicine-B (02137.HK) released new data from two Phase 2 studies at the European Liver Association Congress in 2024. These data evaluated the efficacy of BRII-179 and BRII-835 (elebsiran) combined therapy or BRII-179 as an adjuvant therapy combined with pegylated interferon α (PEG-IFNα) in the treatment of chronic hepatitis B virus (HBV) infection. Oral report data from a Phase 2 clinical trial showed that in some chronic HBV-infected subjects, the therapeutic vaccine, BRII
Tengsheng Pharmaceutical-B (02137.HK): BRII-835 and BRII-877 were recognized as breakthrough therapeutic varieties
On May 14, Gelonghui | Tengshengbo Pharmaceutical-B (02137.HK) announced that the Drug Evaluation Center of the China State Drug Administration will include the hepatitis B virus (“HBV”) specific broad-spectrum neutralizing monoclonal antibody BRII-877 (tobevibart) and the HBV-targeted small-interfering ribonucleic acid BRII-835 (elebsiran) under development as breakthrough therapeutic varieties. This is after the recombinant protein-based HBV immunotherapy BRII-179 was certified as a breakthrough treatment in November 2023, and the company is seeking functional treatment for HBV
Tengsheng Pharmaceutical-B (02137): The HBV-specific broad-spectrum neutralizing monoclonal antibody BRII-877 (tobevibart) and the HBV-targeted small interfering ribonucleic acid BRII-835 (elebsiran) were recognized as breakthrough therapeutic varieties
Tengsheng Pharmaceutical-B (02137) announced that the Drug Evaluation Center of China's State Drug Administration will be developing type B...
BRII-B: 2023 Annual Report
Tengsheng Pharmaceutical-B (02137) granted a total of 5.752,500 share options and 821,500 restricted share units
Tengsheng Pharmaceutical-B (02137) issued an announcement. On March 28, 2024, the company purchased shares in accordance with 2023...
Tengsheng Pharmaceutical-B (02137.HK) will actively seek external cooperation with R&D expenditure of 403 million yuan in 2023
Gelonghui, March 22 | Tengsheng Pharmaceutical-B (02137.HK) announced that for the year ended December 31, 2023, other revenue was RMB 163.7 million, an increase of RMB 55.8 million or 51.7% compared with RMB 107.9 million for the year ended December 31, 2022. This was mainly due to an increase in interest income of RMB 70.8 million due to rising interest rates on US dollar and Hong Kong dollar time deposits. This increase was partially offset by a reduction in revenue recognized by the Chinese government subsidy. For the year ended December 31, 2023, R&D expenditure was for the people
BRII-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2023
Tengsheng Pharmaceutical-B (02137.HK) will hold a board meeting on March 22 to approve the annual results
Gelonghui March 11 | Tengsheng Pharmaceutical-B (02137.HK) issued an announcement. The company will hold a board meeting on March 22, 2024 to review and approve the company's annual results and announcements for the year ended December 31, 2023.
BRII-B: DATE OF BOARD MEETING
After falling nearly 45% in two days and excluding Hong Kong Stock Connect, Tengsheng Pharmaceutical-B (02137) was seriously injured?
As the stock with the worst decline on the list, the reason behind the successive sharp declines of Tengsheng Pharmaceutical-B is not just an appearance on paper.
Here's Why We're Watching Brii Biosciences' (HKG:2137) Cash Burn Situation
Changes in Hong Kong stocks | Tengsheng Pharmaceutical-B (02137) fell more than 26%, and its stock price hit a new low and was removed from the Hong Kong Stock Connect list
The Zhitong Finance App learned that Tengsheng Pharmaceutical-B (02137) fell by more than 26%, and the intraday low of HK$1.22 hit a new low since listing. As of press release, it decreased by 26.47% to HK$1.25, with a turnover of HK$20.313,900. According to the news, according to the Hong Kong Stock Exchange and the Hong Kong Stock Exchange's adjustment announcements issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange, Tengsheng Pharmaceuticals has been removed from the Hong Kong Stock Connect list, which will take effect today. According to reports, Tengsheng Pharmaceutical announced the discontinuation of production of the COVID-19 neutralizing antibody last year. It is its only commercial product, contributing all of its revenue in 2022. In 2022, the company lost 484 million yuan
Guojin Securities: Chronic Hepatitis B Cure Track has broad potential market space and continues to recommend companies that deploy long-acting interferons and related innovative drugs
The chronic hepatitis B cure track is one of the tracks that the trip continues to be optimistic about and recommended. Clinical cure for chronic hepatitis B has now entered a new stage from early exploration to international recognition to rapid and in-depth development.
Changes in Hong Kong stocks | Tengsheng Pharmaceutical-B (02137) rose more than 9% intraday and recently acquired HBV Pharmaceuticals' intellectual property rights and cancer vaccine development rights in the Asia-Pacific region
Tengsheng Pharmaceutical-B (02137) rose more than 9% in the intraday period. As of press release, it was up 5.14% to HK$1.84, with a turnover of HK$4.926,300.
Analysis
Price Target
No Data
